Skip to main content

Shawver Laura's Form 4 filing

ARS Pharmaceuticals, Inc.SPRY · filed Dec 4, 2024

Accession no.
0001415889-24-028350
Filed
Dec 4, 2024
Trade date
Dec 2-4, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions and 5 derivative transactions. Open-market sales total $2.69M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shawver LauraCIK 0001551891Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2024Common StockMOption exerciseAcquired+67,616$1.27+$85,872.32277,962Direct
Dec 2, 2024Common StockMOption exerciseAcquired+29,628$1.27+$37,627.56307,590Direct
Dec 2, 2024Common StockSSaleDisposed−96,343$13.55F2−$1,305,447.65211,247Direct
Dec 2, 2024Common StockSSaleDisposed−901$14.34F3−$12,920.34210,346Direct
Dec 3, 2024Common StockMOption exerciseAcquired+25,606$1.27+$32,519.62235,952Direct
Dec 3, 2024Common StockMOption exerciseAcquired+62,378$3.15+$196,490.7298,330Direct
Dec 3, 2024Common StockSSaleDisposed−87,984$13.26F4−$1,166,667.84210,346Direct
Dec 4, 2024Common StockMOption exerciseAcquired+14,772$3.15+$46,531.8225,118Direct
Dec 4, 2024Common StockSSaleDisposed−14,772$13.75F5−$203,115210,346Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 2, 2024Common StockMOption exerciseDisposed−29,628$0.00$025,606Direct
Dec 2, 2024Common StockMOption exerciseDisposed−67,616$0.00$00Direct
Dec 3, 2024Common StockMOption exerciseDisposed−25,606$0.00$00Direct
Dec 3, 2024Common StockMOption exerciseDisposed−62,378$0.00$073,836Direct
Dec 4, 2024Common StockMOption exerciseDisposed−14,772$0.00$059,064Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The weighted average sale price for the transaction reported was $13.5539 and the range of prices were between $13.27 and $14.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F3

The weighted average sale price for the transaction reported was $14.3417 and the range of prices were between $14.2761 and $14.375. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F4

The weighted average sale price for the transaction reported was $13.2626 and the range of prices were between $12.92 and $13.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

F5

The weighted average sale price for the transaction reported was $13.7496 and the range of prices were between $13.39 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)